NGM Biopharmaceuticals Current Ratio 2018-2021 | NGM

NGM Biopharmaceuticals current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
NGM Biopharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.40B $0.05B 8.95
2021-03-31 $0.43B $0.04B 10.57
2020-12-31 $0.31B $0.04B 7.24
2020-09-30 $0.30B $0.04B 8.01
2020-06-30 $0.32B $0.03B 9.57
2020-03-31 $0.34B $0.03B 11.89
2019-12-31 $0.36B $0.04B 8.94
2019-09-30 $0.36B $0.04B 9.00
2019-06-30 $0.37B $0.04B 9.53
2019-03-31 $0.20B $0.04B 4.64
2018-12-31 $0.22B $0.04B 5.17
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.473B $0.087B
NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86